PhilArchive
open access
Off-Label Prescription of COVID-19 Vaccines in Children: Clinical, Ethical, and Legal Issues
We argue that the universal recommendations against “off-label” pediatric use of approved COVID-19 issued by the FDA, CDC, and AAP are overbroad. Especially for higher-risk children, vaccination can be ethically justified even before FDA authorization or approval – and similar reasoning is relevant for even younger patients. Legal risks can also be managed, although the FDA, CDC, and Department of Health and Human Services (HHS) should move quickly to provide clarity.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Payers should cover COVID-19 vaccines for all ages and risk groups with no patient cost sharing.#1159055
- COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources#724053
- Should we delay covid-19 vaccination in children?#734506
- COVID-19 vaccine trial ethics once we have efficacious vaccines#776793
- Making Better Informed, More Confident COVID-19 Decisions: Vaccine Hesitancy, Its Barriers and Impact Studies: Taking Bayelsa State as an Example#85232
Record · ID 760084
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive